Clinical

Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).

There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.

A look at the psychological implications of acne in teenagers and adults.

Discussion on the economic burden of over-counter and prescription drug costs related to acne therapy.

Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.

Interviews on research presented at the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany

Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties inherent in making CRISPR gene editing technology an equitable treatment.

Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.

The study also found people with vitamin D deficiency had a lower mortality rate from Clostridioides difficile infection (CDI).

This rare adverse effect was witnessed in a small number of people post vaccine administration.

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

Researchers found that patients with chronic obstructive pulmonary disorder (COPD) with higher Systemic Immune-Inflammation Index (SII) levels have a greater risk of all-cause mortality.

Even patients with diffuse large B-cell lymphoma who are eligible for chimeric antigen receptor (CAR) T-cell therapy face multiple barriers to care and need assistance.

The targeted therapy already has indications in acute myeloid leukemia.

A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe and effective.

The researchers found that methods of physical activity data collection and processing for patients with interstitial lung disease (ILD) were difficult to interpret and to compare with other disease states.

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

Stroke of an undetermined cause was associated with acute symptomatic seizures, an effect that was marginally mediated by cerebral microbleeds.

Dr Carney drives a discussion surrounding optimal treatment strategies for schizophrenia.

Panelists provide insight into the standards of care for treating patients diagnosed with schizophrenia.

This study compared autoantigen detection of acetylcholine receptor and muscle-specific kinase, among 3 assays used in suspected cases of myasthenia gravis.

Use of SignalPath will improve efficiency, ease compliance, boost enrollment, and ensure financial success in clinical trials, leaders said in interviews.

New research demonstrated varying trends in early-onset cancer incidence based on race, sex, age, and cancer type.

Researchers found that infections and antibiotic use appear to affect the development of late-onset atopic dermatitis (AD), with respiratory infections having a particularly strong influence.

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

The CDC made this recommendation after reviewing relevant literature and noting that complete testing jumped from about only two-thirds of patients to nearly all patients.

Theory-based smoking cessation interventions helped to motivate patients with chronic obstructive pulmonary disease (COPD) who smoke to quit, ultimately improving their quality of life and lung function.